Rixathon 500 mg is a biosimilar of rituximab, a monoclonal antibody used to treat certain blood cancers and autoimmune diseases. It is primarily indicated for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), where it targets a specific protein called CD20 found on the surface of B-cells (a type of white blood cell). By binding to CD20, Rixathon triggers the destruction of these abnormal B-cells, helping to control the growth and spread of cancer. In addition to cancer treatment, Rixathon is also used to manage rheumatoid arthritis (in combination with methotrexate) and other autoimmune conditions like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), where the immune system mistakenly attacks healthy tissues. The medicine is administered via intravenous (IV) infusion in a clinical setting, with dosage and frequency depending on the condition being treated and patient response.

Rixathon has proven effective in improving outcomes for patients, but it also requires careful monitoring due to the risk of serious side effects. Common adverse reactions include infusion-related reactions, such as fever, chills, and nausea, especially during the first infusion. Other potential side effects include low blood cell counts, infections, fatigue, and in rare cases, serious allergic or immune-related reactions such as progressive multifocal leukoencephalopathy (PML), a rare brain infection. Because of these risks, patients are closely monitored before, during, and after infusions. Despite these precautions, Rixathon has significantly improved the management of certain cancers and autoimmune diseases by offering a targeted approach to eliminate harmful B-cells while preserving other parts of the immune system.